DK2065384T3 - Tricyklisk thrombinreceptor-antagonist - Google Patents

Tricyklisk thrombinreceptor-antagonist

Info

Publication number
DK2065384T3
DK2065384T3 DK09150995.0T DK09150995T DK2065384T3 DK 2065384 T3 DK2065384 T3 DK 2065384T3 DK 09150995 T DK09150995 T DK 09150995T DK 2065384 T3 DK2065384 T3 DK 2065384T3
Authority
DK
Denmark
Prior art keywords
receptor antagonist
thrombin receptor
tricyclic thrombin
tricyclic
antagonist
Prior art date
Application number
DK09150995.0T
Other languages
English (en)
Inventor
Samuel Chackalamannil
William J Greenlee
Yuguang Wang
Yan Xia
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29250954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2065384(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK2065384T3 publication Critical patent/DK2065384T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK09150995.0T 2002-04-16 2003-04-14 Tricyklisk thrombinreceptor-antagonist DK2065384T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37307202P 2002-04-16 2002-04-16
EP07016461A EP1860106B1 (en) 2002-04-16 2003-04-14 Tricyclic thrombin receptor antagonists

Publications (1)

Publication Number Publication Date
DK2065384T3 true DK2065384T3 (da) 2011-05-02

Family

ID=29250954

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03718393T DK1495018T3 (da) 2002-04-16 2003-04-14 Tricykliske trombinreceptorantagonister
DK09150995.0T DK2065384T3 (da) 2002-04-16 2003-04-14 Tricyklisk thrombinreceptor-antagonist

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03718393T DK1495018T3 (da) 2002-04-16 2003-04-14 Tricykliske trombinreceptorantagonister

Country Status (34)

Country Link
US (3) US7304078B2 (da)
EP (5) EP2065384B1 (da)
JP (2) JP4558331B2 (da)
KR (1) KR101026929B1 (da)
CN (1) CN1659162B (da)
AR (1) AR039570A1 (da)
AT (3) ATE378330T1 (da)
AU (1) AU2003221932B2 (da)
BR (1) BRPI0309309B8 (da)
CA (1) CA2482858C (da)
CY (3) CY1107184T1 (da)
DE (3) DE60331114D1 (da)
DK (2) DK1495018T3 (da)
EC (1) ECSP045368A (da)
ES (3) ES2297150T7 (da)
FR (1) FR15C0047I2 (da)
HK (3) HK1070887A1 (da)
IL (1) IL164585A (da)
LT (1) LTC1495018I2 (da)
LU (1) LU92759I2 (da)
MX (1) MXPA04010308A (da)
MY (1) MY144040A (da)
NL (1) NL300746I2 (da)
NO (2) NO330500B1 (da)
NZ (2) NZ575139A (da)
PE (1) PE20040412A1 (da)
PL (1) PL214718B1 (da)
PT (2) PT1495018E (da)
RU (2) RU2329264C9 (da)
SG (1) SG164279A1 (da)
SI (2) SI2065384T1 (da)
TW (1) TWI343919B (da)
WO (1) WO2003089428A1 (da)
ZA (1) ZA200408342B (da)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20040192753A1 (en) * 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) * 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7442712B2 (en) * 2004-05-28 2008-10-28 Schering Corporation Constrained himbacine analogs as thrombin receptor antagonists
JP2008515908A (ja) * 2004-10-06 2008-05-15 ユニバーシティー オブ ロチェスター 組織因子経路を阻害する薬剤を使用する、肺高血圧症の治療
ATE458726T1 (de) * 2005-01-14 2010-03-15 Schering Corp Exo- und diastereoselektive synthese von himbacin-analoga
AR052871A1 (es) * 2005-01-14 2007-04-11 Schering Corp Una sintesis exo-selectiva de analogos de himbacina
CA2594741A1 (en) * 2005-01-14 2006-07-20 Schering Corporation Synthesis of himbacine analogs
US20060172397A1 (en) * 2005-01-14 2006-08-03 Schering Corporation Preparation of chiral propargylic alcohol and ester intermediates of himbacine analogs
US7541471B2 (en) * 2005-01-14 2009-06-02 Schering Corporation Synthesis of himbacine analogs
WO2006105217A2 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
WO2007075808A2 (en) * 2005-12-20 2007-07-05 Schering Corporation Methods for preventing and/or treating a cell proliferative disorder
US20070202140A1 (en) * 2005-12-22 2007-08-30 Veltri Enrico P Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
TW200812619A (en) * 2006-04-06 2008-03-16 Schering Corp TRA combination therapies
MX2008013246A (es) 2006-04-13 2008-10-21 Schering Corp Antagonistas del receptor de trombina de anillo fusionado.
CA2655720A1 (en) * 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
TWI367112B (en) * 2006-06-30 2012-07-01 Schering Corp Immediate-release tablet formulations of a thrombin receptor antagonist
AR061727A1 (es) * 2006-06-30 2008-09-17 Schering Corp Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato
DE102006036023A1 (de) 2006-08-02 2008-02-07 Sanofi-Aventis Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
KR20090058583A (ko) * 2006-10-04 2009-06-09 쉐링 코포레이션 힘바신의 개질된 트리사이클릭 단위를 기본으로 하는 트롬빈 수용체 길항제
EP2069326B1 (en) 2006-10-04 2015-03-18 Merck Sharp & Dohme Corp. Bicyclic and tricyclic derivatives as thrombin receptor antagonists
CA2673228A1 (en) * 2006-12-22 2008-07-03 Schering Corporation Disintegration promoters in solid dose wet granulation formulations
CA2681597A1 (en) * 2007-03-23 2008-10-02 Schering Corporation Reduction of adverse events after percutaneous intervention by use of a thrombin receptor antagonist
EP2240486B1 (de) 2008-02-05 2015-09-09 Sanofi Triazoliumsalze als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
PT2240487E (pt) 2008-02-05 2012-03-08 Sanofi Sa Triazolopiridazinas como inibidores do par1, sua preparação e utilização como produtos farmacêuticos
WO2009124103A2 (en) * 2008-04-02 2009-10-08 Schering Corporation Combination therapies comprising par1 antagonists with par4 antagonists
MX2010012635A (es) 2008-05-19 2010-12-06 Schering Corp Compuestos heterociclicos como inhibidores de factor ixa.
JP5789256B2 (ja) * 2009-06-04 2015-10-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． トロンビン受容体アンタゴニストの活性代謝物
CA2764172A1 (en) 2009-06-08 2010-12-16 Schering Corporation A thrombin receptor antagonist and clopidogrel fixed dose tablet
TWI393716B (zh) 2009-08-04 2013-04-21 Merck Sharp & Dohme 作為ｉｘａ因子抑制劑之雜環化合物
PL2558465T3 (pl) 2010-04-16 2015-05-29 Sanofi Sa Trycykliczne pirydylo-winylo-pirole jako inhibitory receptora aktywowanego proteazą 1 (PAR1)
WO2011128420A1 (de) 2010-04-16 2011-10-20 Sanofi Pyridyl-vinyl-pyrazolo-chinoline als par1-inhibitoren
KR101303348B1 (ko) 2010-06-25 2013-09-03 한국화학연구원 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물
EP2822557B1 (en) 2012-03-06 2017-08-23 Merck Sharp & Dohme Corp. Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists
US9604971B2 (en) 2013-07-22 2017-03-28 Aralez Pharmaceuticals Trading Dac Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin
EP3035928B1 (en) 2013-08-22 2023-10-18 Merck Sharp & Dohme LLC 3'-pyridyl substituted- 6,6-difluoro bicyclic himbacine derivatives
US20160200715A1 (en) 2013-08-22 2016-07-14 Merck Sharp & Dohme Corp. Preparation and use of 7a-heterocycle substituted- 6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists
US9701669B2 (en) 2013-08-22 2017-07-11 Merck Sharp & Dohme Corp. Preparation and use of 7a-amide substituted- 6,6-difluoro bicyclic himbacine derivatives as PAR-1 receptor antagonists
FR3014693B1 (fr) 2013-12-16 2016-01-08 Pf Medicament Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105985303B (zh) * 2015-02-13 2020-08-14 上海彩迩文生化科技有限公司 抗凝血剂的制备方法、中间体及其制备方法
CN106478608A (zh) * 2015-09-01 2017-03-08 博瑞生物医药（苏州）股份有限公司 沃拉帕沙的硫酸盐的结晶多晶型物
CN106749201A (zh) * 2015-11-25 2017-05-31 博瑞生物医药（苏州）股份有限公司 一种沃拉帕沙及其中间体的制备方法
WO2017134200A1 (en) * 2016-02-05 2017-08-10 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of vorapaxar and metoprolol
TR201601548A2 (tr) * 2016-02-05 2018-03-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu
WO2017181993A1 (zh) * 2016-04-22 2017-10-26 江苏天士力帝益药业有限公司 一种新的喜巴辛类似物及其在医药中的应用
CN106236779A (zh) * 2016-08-22 2016-12-21 孔五 一种脐带血富血小板血浆prp的制备方法
FR3090317B1 (fr) 2018-12-19 2021-05-07 Cvasthera Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale
CN110407819B (zh) * 2019-08-02 2020-06-26 牡丹江医学院 一种作为预防外科手术并发症的凝血酶受体拮抗剂
US20210113536A1 (en) * 2019-10-21 2021-04-22 United States Government as Represented by the Department of Veteran Affairs Methods and compositions for detecting and treating venous thromboembolism
FR3109089B1 (fr) 2020-04-08 2023-04-14 Cvasthera Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales
EP4185587A1 (en) 2020-07-22 2023-05-31 JANSSEN Pharmaceutica NV Compounds useful as factor xia inhibitors
US11919881B2 (en) 2021-03-18 2024-03-05 Janssen Pharmaceutica Nv Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11845748B2 (en) 2021-03-18 2023-12-19 Janssen Pharmaceutica Nv Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11814364B2 (en) 2021-03-18 2023-11-14 Janssen Pharmaceutica Nv Pyridine N-oxide derivatives useful as factor XIa inhibitors
EP4070658A1 (de) 2021-04-06 2022-10-12 BIORoxx GmbH Verwendung von blutgerinnungshemmenden verbindungen als rodentizide
US11897880B2 (en) 2021-04-30 2024-02-13 Janssen Pharmaceutica Nv 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en) 2021-07-22 2024-04-16 Janssen Pharmaceutica Nv Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
FR3134314A1 (fr) 2022-04-08 2023-10-13 Cvasthera Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623810B2 (fr) 1987-02-17 1992-01-24 Sanofi Sa Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5576328A (en) 1994-01-31 1996-11-19 Elf Sanofi Method for the secondary prevention of ischemic events
TR200001480T2 (tr) * 1997-11-25 2000-09-21 Schering Corporation Trombin reseptör antagonistleri
US6063847A (en) 1997-11-25 2000-05-16 Schering Corporation Thrombin receptor antagonists
FR2779726B1 (fr) 1998-06-15 2001-05-18 Sanofi Sa Forme polymorphe de l'hydrogenosulfate de clopidogrel
US20040192753A1 (en) 2000-06-15 2004-09-30 Samuel Chackalamannil Methods of use of thrombin receptor antagonists
US7488742B2 (en) 2000-06-15 2009-02-10 Schering Corporation Thrombin receptor antagonists
EP2301930B1 (en) * 2000-06-15 2016-01-06 Merck Sharp & Dohme Corp. Derivatives of hexahydrobenzofuranone useful for the treatment of (inter alia) auto-immune or inflammatory disorders
US7037920B2 (en) 2001-10-18 2006-05-02 Schering Corporation Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists

Also Published As

Publication number Publication date
EP1982984A3 (en) 2008-10-29
EP2065384A1 (en) 2009-06-03
RU2329264C9 (ru) 2009-04-20
ATE455774T1 (de) 2010-02-15
CY1107184T1 (el) 2012-10-24
CA2482858A1 (en) 2003-10-30
PT2065384E (pt) 2011-03-16
EP1860106B1 (en) 2010-01-20
CY2015029I2 (el) 2016-04-13
FR15C0047I2 (fr) 2016-05-06
AU2003221932B2 (en) 2007-11-22
LTC1495018I2 (lt) 2017-04-10
IL164585A0 (en) 2005-12-18
DK1495018T3 (da) 2008-02-18
MXPA04010308A (es) 2005-02-03
HK1123302A1 (en) 2009-06-12
KR20040099441A (ko) 2004-11-26
ES2297150T7 (es) 2012-03-16
IL164585A (en) 2010-11-30
PL373332A1 (en) 2005-08-22
RU2004133375A (ru) 2005-07-10
HK1070887A1 (en) 2005-06-30
MY144040A (en) 2011-07-29
NZ575139A (en) 2010-08-27
DE60335679D1 (de) 2011-02-17
EP1982984A2 (en) 2008-10-22
US20070270439A1 (en) 2007-11-22
DE60317493T3 (de) 2018-07-12
CY1111363T1 (el) 2015-08-05
ES2338171T3 (es) 2010-05-04
NL300746I1 (da) 2016-01-21
DE60331114D1 (de) 2010-03-11
US20030216437A1 (en) 2003-11-20
CA2482858C (en) 2010-11-30
SI2065384T1 (sl) 2011-05-31
BRPI0309309B8 (pt) 2021-05-25
AR039570A1 (es) 2005-02-23
PL214718B1 (pl) 2013-09-30
AU2003221932A1 (en) 2003-11-03
US7713999B2 (en) 2010-05-11
CN1659162A (zh) 2005-08-24
WO2003089428A1 (en) 2003-10-30
ES2297150T3 (es) 2008-05-01
DE60317493T2 (de) 2008-09-18
ECSP045368A (es) 2005-01-03
JP2005528406A (ja) 2005-09-22
US20070179187A1 (en) 2007-08-02
NO2015016I2 (no) 2015-07-09
EP1495018A1 (en) 2005-01-12
RU2329264C2 (ru) 2008-07-20
DE60317493D1 (en) 2011-01-13
NL300746I2 (da) 2016-01-21
EP1982984B1 (en) 2013-02-13
SG164279A1 (en) 2010-09-29
NO330500B1 (no) 2011-05-02
ES2357876T3 (es) 2011-05-03
JP4558331B2 (ja) 2010-10-06
US7304078B2 (en) 2007-12-04
CY2015029I1 (el) 2016-04-13
ATE378330T1 (de) 2007-11-15
EP1495018B1 (en) 2007-11-14
TW200404068A (en) 2004-03-16
NO20044963L (no) 2004-11-15
EP1495018B3 (en) 2011-03-16
ZA200408342B (en) 2006-05-31
PE20040412A1 (es) 2004-07-12
EP2062890B1 (en) 2011-01-05
SI1495018T1 (sl) 2008-04-30
PT1495018E (pt) 2008-02-19
CN1659162B (zh) 2011-08-31
NO2015016I1 (no) 2015-07-20
BR0309309A (pt) 2005-02-15
NZ535880A (en) 2007-11-30
EP2062890A1 (en) 2009-05-27
HK1129893A1 (en) 2009-12-11
EP1860106A1 (en) 2007-11-28
FR15C0047I1 (da) 2015-08-28
TWI343919B (en) 2011-06-21
KR101026929B1 (ko) 2011-04-04
BRPI0309309B1 (pt) 2018-09-04
ATE494284T1 (de) 2011-01-15
LU92759I2 (en) 2015-08-31
EP2065384B1 (en) 2011-01-05
RU2008106401A (ru) 2009-08-27
JP2010132710A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
ATE494284T1 (de) Tricyclischer thrombinrezeptorantagonist
NO20051871D0 (no) Opioid reseptorantagonister
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
ATE413400T1 (de) Cgrp-rezeptorantagonisten
IL174538A0 (en) Thrombin receptor antagonists
NO20025965L (no) Trombinreseptor-antagonister
ATE525378T1 (de) Himbacinanaloga als thrombinrezeptorantagonisten
ATE452886T1 (de) Chemokinrezeptorantagonisten
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
IL182355A0 (en) Thrombin receptor antagonists
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
DE60332816D1 (de) Nk1-antagonisten
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
ATE439379T1 (de) Chimärer antagonist anth1
ATE320254T1 (de) Crf receptor antagonisten
TH105710B (th) โอพิออยด์รีเซปเตอร์แอนตะกอนิสต์
DE602004018527D1 (de) Furanderivate als ep4-rezeptorantagonisten
SE0003996D0 (sv) Receptorantagonister